Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
National Institutes of Health · Health and Human Development (2HD) Research Network · +10 more institutions
Abstract
Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be involved in the pathogenesis of preeclampsia. Since soluble endoglin, another antiangiogenic protein, acts together with sFlt1 to induce a severe preeclampsia-like syndrome in pregnant rats, we examined whether it is associated with preeclampsia in women.
We performed a nested case-control study of healthy nulliparous women within the Calcium for Preeclampsia Prevention trial. The study included all 72 women who had preterm preeclampsia ( or =37 weeks), 120 women with gestational hypertension, 120 normotensive women who delivered infants who were small for gestational age, and 120 normotensive controls who delivered infants who were not small for gestational age.
Citation impact
- FWCI
- 85.19
- Percentile
- 100%
- References
- 35
Authors
11- RJRichard J. LevineCorresponding
National Institutes of Health, Health and Human Development (2HD) Research Network, National Institute of Child Health
- CSChun Sing Lam
Beth Israel Deaconess Medical Center, Center for Vascular Biology Research, Harvard University Press
- CQCong Qian
Allied Technology (United States)
- KFKai F. Yu
National Institutes of Health
- SESharon E. Maynard
George Washington University
Topics & keywords
- Preeclampsia
- Medicine
- Liter
- Endoglin
- Gestational age
- Gestation
- Soluble fms-like tyrosine kinase-1
- Internal medicine